Quarterly report pursuant to Section 13 or 15(d)

LIQUIDITY AND GOING CONCERN (Details Narrative)

v3.20.2
LIQUIDITY AND GOING CONCERN (Details Narrative) - USD ($)
1 Months Ended
Jul. 31, 2020
Apr. 07, 2020
Jun. 30, 2020
Sep. 30, 2020
Aug. 06, 2020
Jul. 28, 2020
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Accumulated deficit       $ 295,481,430     $ 192,823,958
Debt face amount       $ 20,000,000    
Cystic Fibrosis Program Related Investment Agreement [Member] | Phase 2 b Clinical trial [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Consideration payment milestone received $ 5,000,000   $ 5,000,000        
Proceeds from investments on achieving milestones     $ 25,000,000        
Remainder payable upon the achievement of the last remaining milestone $ 2,500,000            
Jefferies LLC [Member] | August 2020 Sale Agreement [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Commission percentage         3.00%    
Authorized to offer and sell up of common stock         $ 150,000,000    
K2 HealthVentures LLC And Ankura Trust Company, LLC [Member] | Loan Agreement [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Debt face amount           $ 50,000,000  
Market Offering [Member] | Jefferies LLC [Member] | Maximum [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Number of common stock shares sold   75,000,000